COPD

News

FDA starts review of AZ's COPD blockbuster hope

The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.

News

It turns out COPD may be a laughing matter after all

Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.

News

AZ pays $200m upfront for Sino Bio COPD drug

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

Zymeworks cuts deal to buy Theravance for $929m in cash

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

FDA starts review of AZ's COPD blockbuster hope

It turns out COPD may be a laughing matter after all

AZ pays $200m upfront for Sino Bio COPD drug

Zymeworks cuts deal to buy Theravance for $929m in cash

AZ is three for three with COPD hope tozorakimab

Where others missed, AZ's IL-33 drug hits the mark in COPD

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

COPD

Editor's Picks